Diabetic retinopathy

Translating discoveries to treatments

Thomas W. Gardner, Gregory R. Jackson, David Quillen, Ingrid Scott

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Retinopathy is one of the most dreaded complications of diabetes because blindness is a greater fear than loss of a limb or death (www.lionsclubs.org/EN/content/news news release58.shtml). Fortunately, advances in the control of blood pressure, hyperglycemia, and hyperlipidemia have reduced the risk of visionthreatening retinopathy in persons with diabetes in each of the succeeding decades from the 1960s to the 1990s (1,2). Nevertheless, the number of persons with diabetes is expected to double by the year 2030 particularly in the developing world (3,4), so fundamentally new approaches are urgently needed to prevent more visually impaired persons, particularly in countries with limited access to medical care. Diabetic retinopathy has been viewed from a surgical perspective and ophthalmologists have employed destructive photocoagulation using halogen light or laser sources for 50 years (5). Photocoagulation remains the primary treatment for diabetic retinopathy in the 21st century. It effectively reduces the risk of blindness but is destructive, expensive, and can be uncomfortable. Its mechanism of action is similar to that of gamma radiation for tumors; i.e., to destroy diseased tissue. Photocoagulation does not address the metabolic processes that lead to the development retinopathy and vision loss. Many patients are reluctant to undergo the treatment, and those who have already loss vision often do not fully regain their sight.

Original languageEnglish (US)
Title of host publicationDiabetes
Subtitle of host publicationTranslating Research into Practice
PublisherCRC Press
Pages173-192
Number of pages20
ISBN (Electronic)9781420047363
ISBN (Print)1420043714, 9781420043716
StatePublished - Jan 1 2008

Fingerprint

Light Coagulation
Diabetic Retinopathy
Blindness
Visually Impaired Persons
Halogens
Gamma Rays
Diabetes Complications
Hyperlipidemias
Hyperglycemia
Fear
Lasers
Therapeutics
Extremities
Blood Pressure
Light
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Gardner, T. W., Jackson, G. R., Quillen, D., & Scott, I. (2008). Diabetic retinopathy: Translating discoveries to treatments. In Diabetes: Translating Research into Practice (pp. 173-192). CRC Press.
Gardner, Thomas W. ; Jackson, Gregory R. ; Quillen, David ; Scott, Ingrid. / Diabetic retinopathy : Translating discoveries to treatments. Diabetes: Translating Research into Practice. CRC Press, 2008. pp. 173-192
@inbook{04e2a44939d24e298ee120b695da9e93,
title = "Diabetic retinopathy: Translating discoveries to treatments",
abstract = "Retinopathy is one of the most dreaded complications of diabetes because blindness is a greater fear than loss of a limb or death (www.lionsclubs.org/EN/content/news news release58.shtml). Fortunately, advances in the control of blood pressure, hyperglycemia, and hyperlipidemia have reduced the risk of visionthreatening retinopathy in persons with diabetes in each of the succeeding decades from the 1960s to the 1990s (1,2). Nevertheless, the number of persons with diabetes is expected to double by the year 2030 particularly in the developing world (3,4), so fundamentally new approaches are urgently needed to prevent more visually impaired persons, particularly in countries with limited access to medical care. Diabetic retinopathy has been viewed from a surgical perspective and ophthalmologists have employed destructive photocoagulation using halogen light or laser sources for 50 years (5). Photocoagulation remains the primary treatment for diabetic retinopathy in the 21st century. It effectively reduces the risk of blindness but is destructive, expensive, and can be uncomfortable. Its mechanism of action is similar to that of gamma radiation for tumors; i.e., to destroy diseased tissue. Photocoagulation does not address the metabolic processes that lead to the development retinopathy and vision loss. Many patients are reluctant to undergo the treatment, and those who have already loss vision often do not fully regain their sight.",
author = "Gardner, {Thomas W.} and Jackson, {Gregory R.} and David Quillen and Ingrid Scott",
year = "2008",
month = "1",
day = "1",
language = "English (US)",
isbn = "1420043714",
pages = "173--192",
booktitle = "Diabetes",
publisher = "CRC Press",

}

Gardner, TW, Jackson, GR, Quillen, D & Scott, I 2008, Diabetic retinopathy: Translating discoveries to treatments. in Diabetes: Translating Research into Practice. CRC Press, pp. 173-192.

Diabetic retinopathy : Translating discoveries to treatments. / Gardner, Thomas W.; Jackson, Gregory R.; Quillen, David; Scott, Ingrid.

Diabetes: Translating Research into Practice. CRC Press, 2008. p. 173-192.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Diabetic retinopathy

T2 - Translating discoveries to treatments

AU - Gardner, Thomas W.

AU - Jackson, Gregory R.

AU - Quillen, David

AU - Scott, Ingrid

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Retinopathy is one of the most dreaded complications of diabetes because blindness is a greater fear than loss of a limb or death (www.lionsclubs.org/EN/content/news news release58.shtml). Fortunately, advances in the control of blood pressure, hyperglycemia, and hyperlipidemia have reduced the risk of visionthreatening retinopathy in persons with diabetes in each of the succeeding decades from the 1960s to the 1990s (1,2). Nevertheless, the number of persons with diabetes is expected to double by the year 2030 particularly in the developing world (3,4), so fundamentally new approaches are urgently needed to prevent more visually impaired persons, particularly in countries with limited access to medical care. Diabetic retinopathy has been viewed from a surgical perspective and ophthalmologists have employed destructive photocoagulation using halogen light or laser sources for 50 years (5). Photocoagulation remains the primary treatment for diabetic retinopathy in the 21st century. It effectively reduces the risk of blindness but is destructive, expensive, and can be uncomfortable. Its mechanism of action is similar to that of gamma radiation for tumors; i.e., to destroy diseased tissue. Photocoagulation does not address the metabolic processes that lead to the development retinopathy and vision loss. Many patients are reluctant to undergo the treatment, and those who have already loss vision often do not fully regain their sight.

AB - Retinopathy is one of the most dreaded complications of diabetes because blindness is a greater fear than loss of a limb or death (www.lionsclubs.org/EN/content/news news release58.shtml). Fortunately, advances in the control of blood pressure, hyperglycemia, and hyperlipidemia have reduced the risk of visionthreatening retinopathy in persons with diabetes in each of the succeeding decades from the 1960s to the 1990s (1,2). Nevertheless, the number of persons with diabetes is expected to double by the year 2030 particularly in the developing world (3,4), so fundamentally new approaches are urgently needed to prevent more visually impaired persons, particularly in countries with limited access to medical care. Diabetic retinopathy has been viewed from a surgical perspective and ophthalmologists have employed destructive photocoagulation using halogen light or laser sources for 50 years (5). Photocoagulation remains the primary treatment for diabetic retinopathy in the 21st century. It effectively reduces the risk of blindness but is destructive, expensive, and can be uncomfortable. Its mechanism of action is similar to that of gamma radiation for tumors; i.e., to destroy diseased tissue. Photocoagulation does not address the metabolic processes that lead to the development retinopathy and vision loss. Many patients are reluctant to undergo the treatment, and those who have already loss vision often do not fully regain their sight.

UR - http://www.scopus.com/inward/record.url?scp=79951663847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951663847&partnerID=8YFLogxK

M3 - Chapter

SN - 1420043714

SN - 9781420043716

SP - 173

EP - 192

BT - Diabetes

PB - CRC Press

ER -

Gardner TW, Jackson GR, Quillen D, Scott I. Diabetic retinopathy: Translating discoveries to treatments. In Diabetes: Translating Research into Practice. CRC Press. 2008. p. 173-192